-INCLUSION CRITERIA:

          1. Phase I: Subjects with cytologically or histologically confirmed locally advanced or
             metastatic solid tumor (Cohort 1).

          2. Phase II: Subjects with cytologically or histologically confirmed locally advanced or
             metastatic checkpoint refractory HPV associated malignancies (Cohort 2), or MSS small
             bowel or colorectal cancer (Cohort 3).

             - Cohort 2 includes:

               -  Cervical cancers;

               -  P16+ Oropharyngeal cancers;

               -  Anal cancers;

               -  Vulvar, vaginal, penile, and squamous cell rectal cancers;

               -  Other locally advanced or metastatic solid tumors (e.g. lung, esophagus) that are
                  known HPV+.

          3. Subjects must have received prior first line systemic therapy unless the patient is
             not eligible to receive standard therapy or declines standard treatment after
             appropriate counseling has been provided.

          4. Patients with checkpoint refractory HPV associated malignancies (Cohort 2) must have
             progressed on prior anti PD-1(L1) therapy. Patients in Cohort 1 and Cohort 3 can be
             checkpoint na(SqrRoot) ve or check point refractory.

          5. Subjects must have measurable disease, per RECIST 1.1.

          6. Age >=18 years.

          7. ECOG performance status < 2

          8. Adequate hematologic function at screening, as follows:

               -  Absolute neutrophil count (ANC) >=1.5 x 10^9/L;

               -  Hemoglobin >= 9 g/dL;

               -  Platelets >= 100,000/microliter.

          9. Adequate renal and hepatic function at screening, as follows:

               -  Measured or calculated creatinine clearance (using the Cockcroft-Gault equation)
                  > 50 mL/min

               -  Bilirubin 1.5 x ULN OR in subjects with Gilbert s syndrome, a total bilirubin <=
                  3.0 x ULN

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN,

             unless liver metastases are present, then values must be 3 x ULN).

         10. The effects of the immunotherapies on the developing human fetus are unknown. For this
             reason and because immunotherapeutic agents as well as other therapeutic agents used
             in this trial are known to be teratogenic, women of child-bearing potential and men
             must agree to use highly effective contraception (hormonal or barrier method of birth
             control; abstinence) at the study entry and for 4 months after the last bintrafusp
             alfa dose, 3 months after the last entinostat dose and 2 months after the last
             NHS-IL12 dose, whichever occurs later. Should a woman become pregnant or suspect she
             is pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately.

         11. Patients serologically positive for HIV, Hep B, Hep C are eligible as long as the
             viral loads are undetectable by quantitative PCR. HIV positive patients must have CD4
             count >= 200 cells per cubic millimeter at enrollment, be on stable antiretroviral
             therapy for at least 4 weeks and have no reported opportunistic infections or
             Castleman's disease within 12 months prior to enrollment.

         12. Subjects must be able to understand and be willing to sign a written informed consent
             document.

        EXCLUSION CRITERIA:

          1. Patients with prior investigational drug, chemotherapy, immunotherapy or any prior
             radiotherapy (except for palliative bone directed therapy) within the past 28 days
             prior to enrollment except if the investigator has assessed that all residual
             treatment-related toxicities have resolved or are at grade 1 severity and feel the
             patient is otherwise suitable for enrollment.

          2. Administration of live vaccine within 30 days prior to enrollment

          3. Major surgery within 28 days prior to enrollment (minimally invasive procedures such
             as diagnostic biopsies are permitted).

          4. Known active brain or central nervous system metastasis (less than a month out from
             definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (<3
             months) or clinically significant cerebrovascular accident (<3 months). In order to be
             eligible patients must have repeat CNS imaging at least a month after definitive
             treatment showing CNS disease that has not progressed. Patients with CNS disease that
             has not progressed at least a month after definitive treatment and continued on <=10
             mg of prednisone (or equivalent) for treatment of brain or central nervous system
             metastasis are eligible to enroll in this study. Patients with evidence of
             intratumoral or peritumoral hemorrhage on baseline imaging are also excluded unless
             the hemorrhage is grade <= 1 and has been shown to be stable on two consecutive
             imaging scans.

          5. Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent with exception of:

               -  Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid
                  disease or other mild autoimmune disorders not requiring immunosuppressive
                  treatment;

               -  Administration of steroids for other conditions through a route known to result
                  in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)
                  is acceptable;

          6. Subjects on systemic intravenous or oral corticosteroid therapy with the exception of
             hormone replacement or physiologic doses of corticosteroids (<= the equivalent of
             prednisone 10 mg/day) or other immunosuppressive drugs such as azathioprine or
             cyclosporin A are excluded on the basis of potential immune suppression. For these
             subjects these excluded treatments must be discontinued at least 1 weeks prior to
             enrollment for recent short course use (<= 14 days) or discontinued at least 4 weeks
             prior to enrollment for long term use (> 14 days). In addition, the use of
             corticosteroids as premedication for contrast-enhanced studies is allowed prior to
             enrollment and on study.

          7. Subjects with a history of serious intercurrent chronic or acute illness, such as
             cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3
             months before enrollment) clinically significant bleeding events, or other illness or
             medical condition considered by the Investigator as high risk for investigational drug
             treatment.

          8. Subjects with conditions associated with significant necrosis of nontumor-bearing
             tissues: esophageal or gastroduodenal ulcers < 6 months prior to enrollment, organ
             infarction < 6 months prior to enrollment, or active ischemic bowel disease.

          9. Presence of medically significant third space fluid (symptomatic pericardial effusion,
             ascites or pleural effusion requiring repetitive paracentesis).

         10. History of second malignancy within 3 years of enrollment except for the following:
             adequately treated localized skin cancer, cervical carcinoma in situ, superficial
             bladder cancer, or other localized malignancy which has been adequately treated or
             malignancy

             which does not require active systemic treatment (e.g. low risk chronic lymphocytic
             leukemia (CLL)).

         11. Subjects with a known severe hypersensitivity reaction to compounds of similar
             chemical or biologic composition to any of study drugs (grade >/= 3 NCI-CTCAE v5) will
             be evaluated by the allergy/immunology team prior to enrollment.

         12. Pregnant women are excluded from this study because these drugs have not been tested
             in pregnant women and there is potential for teratogenic or abortifacient effects.
             Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with these immunotherapies, breastfeeding should
             be discontinued if the mother is treated on this protocol.